LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Apellis Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

17.41 -5.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.35

Max

18.37

Belangrijke statistieken

By Trading Economics

Inkomsten

-56M

-92M

Verkoop

-46M

167M

EPS

-0.74

Winstmarge

-55.292

Werknemers

705

EBITDA

-56M

-80M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+93.75% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-333M

2.2B

Vorige openingsprijs

22.79

Vorige sluitingsprijs

17.41

Nieuwssentiment

By Acuity

50%

50%

162 / 380 Rangschikking in Healthcare

Apellis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 jun 2025, 20:51 UTC

Winsten

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Marktinformatie

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Marktinformatie

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Marktinformatie

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Marktinformatie

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Marktinformatie

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Acquisities, Fusies, Overnames

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Acquisities, Fusies, Overnames

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Acquisities, Fusies, Overnames

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Acquisities, Fusies, Overnames

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Acquisities, Fusies, Overnames

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Marktinformatie

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Marktinformatie
Winsten

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Marktinformatie

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Marktinformatie

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Marktinformatie

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Winsten

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Acquisities, Fusies, Overnames

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 jun 2025, 16:22 UTC

Winsten

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 jun 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

27 jun 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

27 jun 2025, 15:59 UTC

Marktinformatie

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 jun 2025, 15:56 UTC

Marktinformatie

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer Vergelijking

Prijswijziging

Apellis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

93.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.65 USD  93.75%

Hoogste 60 USD

Laagste 18 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Apellis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

10

Buy

8

Hold

0

Sell

Sentiment

By Acuity

162 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.